Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2002 | 1 |
2022 | 1 |
2023 | 2 |
2024 | 2 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity.
Nature. 2022 Nov;611(7934):148-154. doi: 10.1038/s41586-022-05272-1. Epub 2022 Sep 28.
Nature. 2022.
PMID: 36171287
Free PMC article.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA.
de Haas SL, et al. Among authors: lewis gd.
Breast Cancer Res. 2023 Jan 11;25(1):2. doi: 10.1186/s13058-022-01587-z.
Breast Cancer Res. 2023.
PMID: 36631725
Free PMC article.
Clinical Trial.
Item in Clipboard
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Denkert C, Lambertini C, Fasching PA, Pogue-Geile KL, Mano MS, Untch M, Wolmark N, Huang CS, Loibl S, Mamounas EP, Geyer CE, Lucas PC, Boulet T, Song C, Lewis GD, Nowicka M, de Haas S, Basik M.
Denkert C, et al. Among authors: lewis gd.
Clin Cancer Res. 2023 Apr 14;29(8):1569-1581. doi: 10.1158/1078-0432.CCR-22-1989.
Clin Cancer Res. 2023.
PMID: 36730339
Free PMC article.
Item in Clipboard
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Lewis GD, Li G, Guo J, Yu SF, Fields CT, Lee G, Zhang D, Dragovich PS, Pillow T, Wei B, Sadowsky J, Leipold D, Wilson T, Kamath A, Mamounas M, Lee MV, Saad O, Choeurng V, Ungewickell A, Monemi S, Crocker L, Kalinsky K, Modi S, Jung KH, Hamilton E, LoRusso P, Krop I, Schutten MM, Commerford R, Sliwkowski MX, Cho E.
Lewis GD, et al.
Nat Commun. 2024 Jan 11;15(1):466. doi: 10.1038/s41467-023-44533-z.
Nat Commun. 2024.
PMID: 38212321
Free PMC article.
Clinical Trial.
Item in Clipboard
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Clardy SM, Uttard A, Du B, Catcott KC, Lancaster KL, Ditty E, Sadowsky J, Zurita J, Malli N, Qin L, Bradley SP, Avocetien K, Carter T, Kim D, Nazzaro M, Xu L, Pillow TH, Zacharias NT, Lewis GD, Rowntree RK, Iyengar R, Lee DH, Damelin M, Toader D, Lowinger TB.
Clardy SM, et al. Among authors: lewis gd.
Mol Cancer Ther. 2024 Jan 3;23(1):84-91. doi: 10.1158/1535-7163.MCT-23-0262.
Mol Cancer Ther. 2024.
PMID: 37774393
Item in Clipboard
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX.
Agus DB, et al. Among authors: lewis gd.
Cancer Cell. 2002 Aug;2(2):127-37. doi: 10.1016/s1535-6108(02)00097-1.
Cancer Cell. 2002.
PMID: 12204533
Free article.
Item in Clipboard
Cite
Cite